Antitumor necrosis factor (TNF) agents, including infliximab, adalimumab, golimumab, and certolizumab, are effective for induction and maintenance of remission in patients with IBD and reduce the risk of surgery and mortality.[1,2] However, long-term usage of anti-TNF agents is associated with complications, such as infection, postoperative wound healing failure, malignancy, and immune-mediated diseases.[3,4] Psoriasis, one of the immune-mediated diseases, can occur in IBD patients with anti-TNF agents, but ironically anti-TNF agents are also effective to control psoriasis. The gene discussed is TNF; the disease is inflammatory bowel disease.